XML 56 R45.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS' EQUITY (Details Narrative 2) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2013
May 11, 2013
May 31, 2013
May 31, 2012
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
Prepaid expenses - current         $ 337,740   $ 337,740   $ 405,960
Recognition period of unamortized costs             2 years 4 months 24 days    
SCI - Warrants [Member]                  
Exercise price of warrants (in dollars per share)     $ 2.01            
Warrants granted to purchase common stock (shares)     850,000            
Non-cash compensation         0 $ 38,509 $ 0 $ 77,026  
Forfeited warrants granted to purchase common stock (shares)     833,000            
SCI - Warrants [Member] | Tranche One [Member]                  
Fair value of grant $ 405,066                
Non-cash compensation 405,066                
Vesting date of warrants   Jun. 30, 2013              
Expected term   5 years              
Volatility rate   45.89%              
Risk free rate   1.12%              
Dividend yield   0.00%              
Vested warrants granted to purchase common stock (shares)   283,333              
SCI - Warrants [Member] | Tranche Two [Member]                  
Fair value of grant $ 462,196                
Expected term 5 years                
Volatility rate 45.84%                
Risk free rate 1.41%                
Dividend yield 0.00%                
Vested warrants granted to purchase common stock (shares) 283,333                
SCI - Warrants [Member] | Tranche Three [Member]                  
Description of shares to be vested  

283,334 shares will vest upon the receipt by us of any final FDA approval of a drug candidate that SCI helped us design. It is anticipated that this event will occur in the near future.

             
Warrants - Unaffiliated Entity [Member] [Member]                  
Exercise price of warrants (in dollars per share)       $ 2.57          
Fair value of grant       $ 1,532,228          
Warrants granted to purchase common stock (shares)       1,300,000          
Non-cash compensation         $ 64,449 $ 64,449 $ 128,898 $ 128,898  
Expected term       5 years          
Volatility rate       44.71%          
Risk free rate       0.74%          
Dividend yield       0.00%